Clinical Trial Update: Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase I open-label single-dose pharmacokinetics study of NP101 in healthy volunteers was completed, sponsored by NuPathe Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• NP101

Snippet

Sponsor: NuPathe Inc. | Conditions: Migraine Disorders | Phase 1 | Status: COMPLETED